Alvotech (ALVO)
5.19
-0.13
(-2.44%)
USD |
NASDAQ |
Sep 08, 16:00
5.13
-0.06
(-1.16%)
Pre-Market: 09:13
Alvotech Enterprise Value : 3.161B for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 3.161B |
| September 04, 2026 | 3.207B |
| September 03, 2026 | 3.229B |
| September 02, 2026 | 3.214B |
| September 01, 2026 | 3.179B |
| August 31, 2026 | 3.161B |
| August 28, 2026 | 3.075B |
| August 27, 2026 | 3.050B |
| August 26, 2026 | 3.061B |
| August 25, 2026 | 3.111B |
| August 24, 2026 | 3.182B |
| August 21, 2026 | 2.890B |
| August 20, 2026 | 2.833B |
| August 19, 2026 | 2.733B |
| August 18, 2026 | 2.718B |
| August 17, 2026 | 2.693B |
| August 14, 2026 | 2.756B |
| August 13, 2026 | 2.768B |
| August 12, 2026 | 2.740B |
| August 11, 2026 | 2.665B |
| August 10, 2026 | 2.654B |
| August 07, 2026 | 2.669B |
| August 06, 2026 | 2.665B |
| August 05, 2026 | 2.651B |
| August 04, 2026 | 2.679B |
| Date | Value |
|---|---|
| August 03, 2026 | 2.661B |
| July 31, 2026 | 2.779B |
| July 30, 2026 | 2.583B |
| July 29, 2026 | 2.569B |
| July 28, 2026 | 2.415B |
| July 27, 2026 | 2.408B |
| July 24, 2026 | 2.401B |
| July 23, 2026 | 2.444B |
| July 22, 2026 | 2.447B |
| July 21, 2026 | 2.565B |
| July 20, 2026 | 2.526B |
| July 17, 2026 | 2.544B |
| July 16, 2026 | 2.512B |
| July 15, 2026 | 2.515B |
| July 14, 2026 | 2.487B |
| July 13, 2026 | 2.515B |
| July 10, 2026 | 2.479B |
| July 09, 2026 | 2.494B |
| July 08, 2026 | 2.522B |
| July 07, 2026 | 2.554B |
| July 06, 2026 | 2.544B |
| July 02, 2026 | 2.597B |
| July 01, 2026 | 2.586B |
| June 30, 2026 | 2.626B |
| June 29, 2026 | 2.622B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Teva Pharmaceutical Industries Ltd. | 56.05B |
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.82M |
| Revenue (Quarterly) | 105.77M |
| Total Expenses (Quarterly) | 172.59M |
| EPS Diluted (Quarterly) | -0.1873 |
| Gross Profit Margin (Quarterly) | 50.65% |
| Profit Margin (Quarterly) | -63.17% |
| Earnings Yield | -10.74% |
| Operating Earnings Yield | 2.67% |
| Normalized Earnings Yield | -10.74 |